Today's Rundown Featured Story | | | Tuesday, May 21, 2019 Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2α inhibitor that could challenge Keytruda for the metastatic renal cell carcinoma market. |
|
|
Top Stories Tuesday, May 21, 2019 Novartis, Otsuka, Pfizer and Sanofi have signed onto Verily’s Project Baseline, a program aimed at mapping out a baseline for human health. Tuesday, May 21, 2019 The once-straightforward definition of a medical device has begun to stretch. And for that matter, so has the definition of a medical devices company. But 2018’s top FDA green lights made one thing clear: The devices most likely to change a patient's life were designed to change their routines the least. Tuesday, May 21, 2019 Ocular Therapeutix’s drug-eluting insert to treat glaucoma—a small, resorbable hydrogel plug that sits within the tear duct and is designed to replace 90 days’ worth of daily eye drops—fell just short of meeting the primary endpoint of its first pivotal phase 3 trial. Tuesday, May 21, 2019 K2 HealthVentures has secured $400 million to support public and private companies in life sciences and healthcare. The East Coast investor will primarily provide debt financing to enable companies to reach milestones with minimal equity dilution. Monday, May 20, 2019 Researchers at the Icahn School of Medicine at Mount Sinai have shown in a study that Cdx2 cells from the placenta can migrate through the circulatory system and target heart injuries. In male mouse models of heart attack, the cells regenerated damaged tissue. Tuesday, May 21, 2019 Biotech-CRO hybrid Evotec is continuing its deals, buys and collabs strategy with its acquisition of U.S. biologics company Just Biotherapeutics. | This week's sponsor is ExL Events. | |  | |
Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
